Drug firm Mankind Pharma today said it has received licence from the Defence Research and Development Organisation (DRDO) to manufacture and market oral 2-deoxy-D-glucose (2-DG), used for the treatment of COVID-19.
2-DG was developed by the Defence Research and Development Establishment (DRDE), Gwalior. The clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in association with Dr Reddy's Laboratories, Mankind Pharma said in a statement.
The company will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, it added.
The office of the Drugs Controller General of India (DCGI) on May 1 had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe COVID-19 patients, Mankind Pharma said.
The drug is found to help the hospitalised COVID-19 patients recover faster and is also known to reduce the supplemental oxygen dependency among the COVID-19 patients, it added.
"Our objective behind this agreement is to ensure maximum reach of this medication to the deserving Indian patients suffering from the deadly pandemic," the company said.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Video: India Test Fires "Historic" Long-Range Hypersonic Missile India Successfully Conducts Flight Test Of Long Range Land Cruise Missile DRDO Invites Applications For Various Positions, Salary Up To Rs 1.25 Lakh Per Month "Thousand Times Better...": Delhi Lt Governor's Surprise For AAP's Atishi "Violation Of Sovereignty, Abuse Of Power": Kanwal Sibal On US Report On Adani Group 2 Children Strangled To Death In Bengaluru, Parents Blame Each Other: Cops Bushra Bibi Faces Non-Bailable Arrest Warrant In Corruption Case PM Modi Honoured With Global Peace Award For Indian-American Minority Welfare Indian Army Celebrates 77th Anniversary Of Poonch's Historic Link-Up Track Latest News Live on NDTV.com and get news updates from India and around the world.